A phase III trial of higher dose of Qapzola in patients with non-muscle invasive bladder cancer

Trial Profile

A phase III trial of higher dose of Qapzola in patients with non-muscle invasive bladder cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 02 May 2017

At a glance

  • Drugs Apaziquone (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2017 According to a Spectrum Pharmaceuticals media release, this trial is expected to enrolling patients in the third quarter of 2017.
    • 14 Mar 2017 New trial record
    • 08 Mar 2017 According to a Spectrum Pharmaceuticals media release, the company has received a new Special Protocol Agreement (SPA) on this trial from the US FDA and the trial has been designed based on recommendations from the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top